Akankah Kita Melihat $400 Tahun Ini di (NASDAQ: VRTX)?
Keuangan Akankah Kita Melihat $400 Tahun Ini di (NASDAQ: VRTX)? 23 menit yang lalu Berita Bitcoin Ethereum VRTX Pharmaceuticals, Inc. is a biotech company that works on finding, creating, making, and selling small molecule drugs for people with serious diseases. It is based in Boston, MA and was started by Joshua S. Boger in 1989. The company focuses on developing treatments for diseases such as cystic fibrosis, sickle cell disease, pain, and cancer. The VRTX stock‘s latest quarterly report for the period ending June 2023 showed a revenue of $2.48 Billion, a net income of $915.70 Million, and a profit margin of 36.85%. The next quarter’s revenue is estimated to be $2.499 Billion. Vertex reported an EPS of $3.89 for the second quarter, beating analysts‘ estimate of $3.859 by 0.80%. The next quarter’s EPS is estimated to be $3.925. Vertex Group will announce its financial results for the third quarter of 2023 on Wednesday, November 1st, 2023, before the market opens. The Vertex stocks most recent quarterly balance sheet for the period ending June 2023 showed total assets at $20.35 Billion and total liabilities at $4.88 billion. The VRTX stock has a float of 257.177 Million shares and a market cap of $90.212 Billion. The Vertex stock‘s